SCHEMBL24253492

SCHEMBL24253492

CC(C)Cc1cnc2c(c1Cl)CCN(C)C2

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 1/20 0.33
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31
GAA P10253 1/20 0.31
HPGD P15428 1/20 0.31
HTT P42858 1/20 0.31
KAT2B Q92831 1/20 0.31
BRD9 Q9H8M2 1/20 0.31
HSP90AA1 P07900 1/20 0.31
HSP90AB1 P08238 1/20 0.31
HTR2C P28335 2/20 0.30
HTR2B P41595 2/20 0.30
ADRA2A P08913 1/20 0.30
ADRA2B P18089 1/20 0.30
ADRA2C P18825 1/20 0.30
ADRA1D P25100 1/20 0.30
ADRA1A P35348 1/20 0.30
ADRA1B P35368 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24253496 0.88 ADRA2A (0.33) KLKB1ADRA2AADRA2BADRA2CADRA1D
SCHEMBL22981642 0.83 CYP2C19 (0.43) KLKB1ALDH1A1LMNATP53GAA
SCHEMBL24253283 0.80 ALDH1A1 (0.34) ALDH1A1LMNATP53GAAHPGD
SCHEMBL22993421 0.76 ALDH1A1 (0.36) ALDH1A1LMNATP53GAAHPGD
SCHEMBL24253534 0.74 HTR2C (0.42) KAT2BBRD9HTR2CHTR2BADRA2A
SCHEMBL24253296 0.69 GAA (0.34) ALDH1A1LMNATP53GAAHPGD
SCHEMBL22993619 0.69 MAOA (0.35) HTR2CHTR2BADRA2AADRA2BADRA2C
SCHEMBL22993185 0.68 GRIA1 (0.44) KLKB1ALDH1A1LMNAHPGDHTT
SCHEMBL29407318 0.68 GRIA1 (0.44) KLKB1ALDH1A1LMNAHPGDHTT
SCHEMBL19563045 0.66 HTT (0.41) ALDH1A1LMNATP53GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-11613527-B2 Enzyme inhibitors KALVISTA PHARMACEUTICALS LIMITED (GB) 2023-03-28 US disclosed
US-20220048894-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250080-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 KLKB1 2/4885ALDH1A1 1622/4885LMNA 728/4885
US-11613527-B2 Enzyme inhibitors SERPINB1, KLKB1, SERPINE1 KLKB1 2/4885ALDH1A1 1622/4885LMNA 728/4885
US-20220048894-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 KLKB1 2/4885ALDH1A1 1622/4885LMNA 728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.